FY2027 Earnings Estimate for CRSP Issued By Leerink Partnrs

Key Points

• CRISPR Therapeutics is projected to have an EPS of ($4.53) for FY2027, slightly better than the current full-year consensus estimate of ($5.16) per share.
• Various analysts have differing outlooks on the stock, with some lowering target prices while others maintain or increase their "buy" ratings, leading to a consensus rating of "Hold" with an average price target of $69.67.
• Insider transactions included significant selling by Naimish Patel and a substantial purchase by Director Simeon George, indicating mixed signals regarding insider confidence in the company's future performance.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of CRISPR Therapeutics in a research report issued on Monday, August 4th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($4.53) per share for the year. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group cut their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. HC Wainwright reaffirmed a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Bank of America lowered their target price on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $69.67.

CRISPR Therapeutics Trading Down 6.7%

CRSP stock opened at $55.59 on Wednesday. The firm has a 50 day moving average of $50.45 and a 200-day moving average of $43.63. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $71.13. The firm has a market capitalization of $4.80 billion, a P/E ratio of -10.24 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to analysts' expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 19.55%. CRISPR Therapeutics's revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.49) EPS.

Insider Buying and Selling at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares of the company's stock, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Simeon George bought 989,812 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The stock was purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the purchase, the director owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. SVB Wealth LLC bought a new stake in CRISPR Therapeutics in the first quarter valued at $25,000. Costello Asset Management INC bought a new stake in CRISPR Therapeutics in the first quarter valued at $27,000. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics in the fourth quarter valued at $30,000. Atlantic Union Bankshares Corp bought a new stake in CRISPR Therapeutics in the second quarter valued at $33,000. Finally, Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter valued at $36,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.